<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615678</url>
  </required_header>
  <id_info>
    <org_study_id>VINJ007</org_study_id>
    <nct_id>NCT02615678</nct_id>
  </id_info>
  <brief_title>Acupuncture for CIPN in Breast Cancer Patients</brief_title>
  <official_title>Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to collect preliminary data on the effectiveness of acupuncture for&#xD;
      the treatment of CIPN in breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ideally 10 patients experiencing peripheral neuropathy due to chemotherapy from breast cancer&#xD;
      treatment will be included in this study.They will receive 16 total acupuncture treatments&#xD;
      over 10 weeks including various points based off of research and classical text and scalp&#xD;
      acupuncture.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in perceived neuropathy as measured by EORTC CIPN-20</measure>
    <time_frame>At baseline, week 6 (treatment 12) and at week 10 (treatment 16)</time_frame>
    <description>This is a 20-item self-report multidimensional CIPN specific scale that measures sensory, motor and autonomic symptoms of a 1-4 Likert scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in perceived neuropathy as measured by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG) Questionnaire</measure>
    <time_frame>At baseline, week 6 (treatment 12) and at week 10 (treatment 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in perceived neuropathy as measured by Visual Analogue Scale of Pain</measure>
    <time_frame>At baseline, week 6 (treatment 12) and at week 10 (treatment 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life as measured by EORTC QLQ-30</measure>
    <time_frame>At baseline, week 6 (treatment 12) and at week 10 (treatment 16)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sensation Disorders</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture including scalp needling will be applied to selected points based on literature</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Minimum of 18 years of age&#xD;
&#xD;
          2. Currently receiving neurotoxic chemotherapy&#xD;
&#xD;
          3. Experiencing symptoms of chemotherapy induced neuropathy for at least 1 month&#xD;
&#xD;
          4. Have a minimum score of 3 on the VAS should have a grade II CIPN on NCICTC&#xD;
&#xD;
          5. Willing to sign an informed consent&#xD;
&#xD;
          6. Stable treatment for more than two months before screening&#xD;
&#xD;
               -  Stable treatment is defined as no change in the type and dose of medications 2&#xD;
                  months prior to enrollment.&#xD;
&#xD;
               -  Once enrolled, the patients will be asked to remain on the same type and dose of&#xD;
                  the medications for neuropathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving any treatment to prevent neuropathy 2 weeks prior to the screening&#xD;
&#xD;
          2. Pre-existing peripheral neuropathy due to any other cause than chemotherapy&#xD;
&#xD;
          3. Pre-existing conditions like pregnancy, uncontrolled diabetes, hypertension,&#xD;
             cardiovascular disorders, bleeding disorders, depression (BDI &gt; 21)&#xD;
&#xD;
          4. Unwilling to follow the protocol&#xD;
&#xD;
          5. Individuals who are receiving government disability assistance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sivarama Vinjamury, MD, MAOM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California University of Health Sciences, College of Eastern Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California University of Health Sciences</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 21, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Sivarama Vinjamury</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>neuropathy</keyword>
  <keyword>peripheral</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sensation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

